WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > eHealth Initiative
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Pharma Tech
Asahi Kasei | October 17, 2022
Asahi Kasei Pharma, subsidiary of diversified Japanese multinational company Asahi Kasei, is publicly calling for new proposals for drug development research as part of its efforts for open innovation to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes and enterprises around the world. The application period begins at 5:00 a.m. GMT on January 5, 2023 and ends at 8:00 a.m. GMT on February 28, 2023. Asahi Kasei Pharm...
Pharmacy Market
PRNewswire | July 11, 2023
Signant Health, the leader in evidence generation for modern clinical trials, announced expanded flexibility and capabilities for its leading Signant SmartSignals Supplies software, empowering small and mid-size customers to experience the advantages of technology-driven clinical supply management. Relaunched as Signant SmartSignals Supplies GxP Inventory, the solution provides sponsors and contract research organizations (CROs) with efficient, comprehensive management and overs...
BIOCORP and Merck KGaA, Darmstadt, Germany | October 11, 2022
BIOCORP a French company specialized in the design, development, and manufacturing of innovative medical devices, and Merck KGaA, Darmstadt, Germany, a leading science, and technology company, have entered into an agreement for the development and supply of a specific version of Mallya device as an accessory for one of Merck KGaA, Darmstadt, Germany's drug delivery devices. Manufactured in Clermont-Ferrand Mallya is a Bluetooth enabled clip-on device for pen injectors that col...
Research
Gilead | November 21, 2020
Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect...
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE